Advertisement
With this announcement, Schering-Plough has now successfully completed allproduct divestments required by the commitments made to the EuropeanCommission in connection with its approval of its acquisition of OrganonBiosciences in 2007. "We are making good progress both globally and at thecountry level on our integration, and the closing of the transaction withPfizer is another very important step in both that process, as well asfulfilling our acquisition-related commitments to the European Commission. We,Intervet/Schering-Plough Animal Health, offer customers a comprehensiveportfolio and an enhanced range of services building a solid platform forfuture growth," said Ruurd Stolp, President of Intervet/Schering-Plough AnimalHealth.
Advertisement
In Europe, Pfizer acquired products from the parasiticide, swine E. colivaccine, ruminant clostridia vaccine, equine influenza vaccine, ruminantneonatal vaccine, anti-inflammatory, companion animal/insulin and companionanimal/euthanasia, and rabies vaccine franchises of Intervet/Schering-PloughAnimal Health. This agreement does not affect Intervet/Schering-Plough AnimalHealth's marketing of these products in other global markets beyond Europe.
Schering-Plough is an innovation-driven, science-centered global healthcare company. Through its own biopharmaceutical research and collaborationswith partners, Schering-Plough creates therapies that help save and improvelives around the world. The company applies its research-and-developmentplatform to human prescription and consumer products as well as to animalhealth products. Schering-Plough's vision is to "Earn Trust, Every Day" withthe doctors, patients, customers and other stakeholders served by itscolleagues around the world. The company is based in Kenilworth, N.J., and itswebsite is www.schering-plough.com.
SOURCE Schering-Plough Corporation
